Story
Eurofins Scientific Reports Slow H1 Organic Growth, Beats Profit Estimates
Summary
Eurofins Scientific announced first-half organic growth of 2.7%, missing market expectations due to weakness in its biopharma segment, though adjusted EBITDA and earnings per share exceeded consensus forecasts.
Eurofins Scientific reported first-half organic growth that fell short of analyst expectations, citing persistent headwinds in its biopharma and diagnostics businesses. The laboratory testing group's second-quarter organic growth of approximately 3% also missed the consensus estimate of 4.2%, according to the company's latest financial release.
Key Financials Show Mixed Results
Despite the slower top-line growth, Eurofins delivered stronger-than-expected profitability. The company posted first-half revenue of €3.701 billion, which was in line with market consensus, even with a 2.9% headwind from foreign exchange rates.
Key performance indicators for the first half include:
- Adjusted EBITDA: Reached €877 million, 4% above the consensus estimate of €844 million.
- Adjusted EBITDA Margin: Improved by 130 basis points year-over-year to 23.7%, surpassing the forecast of 22.8%.
- Adjusted Earnings Per Share: Rose 25% year-over-year to €1.64.
- Free Cash Flow: Increased 46% year-over-year to €403 million after investments.
Biopharma Weakness Drags on Growth
AdThe company's biopharma segment experienced a sequential decline, contracting by 1.1% in the second quarter after growing 1.1% in the first. Eurofins noted that its contract development and manufacturing organization (CDMO) activity remained weak, while its product testing division was stable.
Geographically, growth in North America remained subdued at 2.0% in the second quarter. Europe saw a marginal improvement, with growth accelerating to 2.3% in the second quarter from 1.6% in the first. The company's net debt to EBITDA ratio held steady at 2.2 times, unchanged from the end of fiscal year 2025.
Outlook Reaffirmed
Eurofins maintained its full-year guidance, continuing to target mid-single-digit organic growth and an adjusted EBITDA margin above the fiscal year 2025 level of 22.5%. The company also expects year-over-year improvement in free cash flow.
Management cautioned that achieving these targets will "depend on the speed of pick-up of business in certain ancillary activities, and the end of contraction in others."
Read next
More on Stocks
Taiwan Weighted Index Closes 0.25% Lower on Sector Weakness
Taiwan's benchmark stock index ended Thursday's session in negative territory, weighed down by losses in the biotech and cement sectors. The decline came despite several individual stocks reaching new all-time highs.
RBI Reportedly Conducts $10 Billion in Currency Swaps to Drain Liquidity
The Reserve Bank of India has carried out at least $10 billion in sell-buy currency swaps in recent weeks to absorb a record cash surplus in the banking system, according to a Bloomberg report.
Tencent Launches TenPayGo App to Simplify Mobile Payments for Foreign Visitors in China
The new app, TenPayGo, allows international travelers to link foreign credit cards and digital wallets for use across the vast WeChat Pay network, aiming to capture a growing inbound tourism market.
Mitchells & Butlers Reports Q4 Sales Growth, Expects FY26 Results to Meet Consensus
The U.K. pub and restaurant operator announced a 1.4% rise in like-for-like sales for the fourth quarter and projected that cost pressures would ease in the upcoming fiscal year.